Post

Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab

Biopharma giant AbbVie has announced it intends to terminate its cancer drug deal with I-Mab, the creators of lemzoparlimab. The …

China’s NMPA approves Henlius’ oesophageal cancer therapy

China’s National Medical Products Administration (NMPA) has granted approval for Shanghai-based Henlius Biotech’s Hansizhuang (serplulimab injection) for use in PD-L1 …

Valneva receives JE vaccine supply contract from US DoD

Valneva has received a contract from the US Department of Defense (DoD) for the delivery of its Japanese encephalitis (JE) …

Merck and ICR enter renewed cancer drug discovery partnership

Merck KGaA (Merck) and the UK's Institute of Cancer Research (ICR) have entered a renewed strategic collaboration to discover and develop new …

Boehringer and Lilly gain FDA approval for kidney disease therapy

Boehringer Ingelheim and Eli Lilly and Company have received approval from the US Food and Drug Administration (FDA) for Jardiance …